Skip to content

Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy

Prospective, International, Randomized, Multicentric, Controlled Study on the Performance of SYMMCORA® Mid-term Unidirectional Barbed Suture Versus V-loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06024109
Acronym
BARHYSTER
Enrollment
132
Registered
2023-09-06
Start date
2024-03-19
Completion date
2027-08-01
Last updated
2026-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abnormal Uterine Bleeding, Cervical Cancer, Endometrial Cancer, Endometriosis, Fallopian Tube Cancer, Ovarian Cancer, Uterine Cancer, Uterine Prolapse

Keywords

Barbed Suture, Hysterectomy, Laparoscopy, Minimal Invasive

Brief summary

The aim of this study is to show the superiority of the new unidirectional barbed suture (SYMMCORA® mid-term, unidirectional) to conventional suture material in terms of time to perform the vaginal cuff closure during gynecologic surgeries without an increase in the complication rate. Secondly, the superiority of SYMMCORA®, mid-term unidirectional compared to the V-Loc®, unidirectional will be assessed regarding the mean time to close the vaginal cuff. The study will be performed in routine clinical setting, the only difference will be the randomization into two different suture groups. Both suture materials which will be applied to approximate the vaginal cuff are approved and carrying the CE-marks. Additionally, both sutures will be applied in their intended use. Neither additional invasive measures nor additional burden in regard to the patient will be performed.

Interventions

DEVICEClosure of the Vaginal Cuff after Total Hysterectomy

Closure of the vaginal cuff in patients undergoing laparoscopic total hysterectomy. The product under investigation and the comparator suture material will be used in routine clinical practice and according to the Instructions for Use (IfU).

Sponsors

Aesculap AG
Lead SponsorINDUSTRY
B.Braun Surgical SA
CollaboratorINDUSTRY

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Females undergoing an elective, laparoscopic total hysterectomy * Age ≥ 18 years * Written informed consent

Exclusion criteria

* Emergency surgery * Open surgery * Patients undergone immunosuppressive drug treatment within the prior 6 months * Patients with hypersensitivity or allergy to the suture material. * Participation in another clinical study * Non-compliance of patient

Design outcomes

Primary

MeasureTime frameDescription
Suturing time to close the vaginal cuffintraoperativelyMeasured in Minutes. Time to perform the vaginal cuff closure after laparoscopic total hysterectomy using a stop watch. Time starts when the needle passes the first time the tissue and ends after completion of the wound closure (cut of the needle from the thread).

Secondary

MeasureTime frameDescription
Number of patients with early complicationsat discharge (up to 10 days after surgery)Documented early complications include Hemoglobin drop and Fever more than 38°C within 48 hours
Number of patients with complications over the study periodat discharge (up to 10 days after surgery), 6-8 weeks postoperatively, 6 months postoperativelyDocumented complications include Vaginal cuff infection, Vaginal cuff dehiscence (Defined as a visually confirmed partial or complete opening of the vaginal stump with or without visceral organ herniation), Vaginal cuff granulation formation, Pelvic Abscess Formation, Hematoma, Vaginal spotting (defined as bloody vaginal discharge that did not require extraordinary procedures or medication and disappeared spontaneously. (Days of postoperative bleeding, Number of pads / tampons used), Vaginal bleeding (Defined as postoperative vaginal stump bleeding that required additional stump suture to stop bleeding. (Days of postoperative bleeding, number of pads / tampons used), Urinary tract infection, Bladder injury, Ureter injury, Bowel obstruction, Ileus, Cystitis and Pelvic Adhesions.
Number of patients with device deficiencies over the study periodintraoperatively, at discharge (up to 10 days after surgery), 6-8 weeks postoperatively, 6 months postoperativelyDocumented device deficiencies include Suture rupture, Knots in the thread, Connection between needle and thread not intact and Disconnection of the anchor from the thread
Patient satisfaction (VAS 0-100) over timeat discharge (up to 10 days after surgery), 6-8 weeks postoperatively, 6 months postoperativelyThe patient's self assessment of her satisfaction with the surgery. This parameter will be noted using the Visual Analogue Scale (VAS), represented by a line 10 cm of length, which states "0" at one end representing "low" and "100" at the opposite end representing "high". The value is measured in \[mm\] with a ruler and documented in whole numbers.
Progress of Female Sexual Function Index (FSFI) compared to baselinePreoperatively (baseline), at follow-up visits 6-8 weeks postoperatively and 6 months postoperativelyThe Female Sexual Function Index (FSFI) is a 19-item, self-report measure of female sexual function that provides scores on overall levels of sexual function as well as the primary components of sexual function in women, including sexual desire, arousal, orgasm, pain, and satisfaction. The 19 items of the FSFI use a 5-point Likert scale ranging from 1-5 with higher scores indicating greater levels of sexual functioning on the respective item. (0 points in some cases for items that are not applicable). To score the measure, the sum of each domain score is first multiplied by a domain factor ratio (0.6 for desire; 0.3 for arousal and lubrication; 0.4 for orgasm, satisfaction and pain) in order to place all domain totals on a more comparable scale, and then subsequently summed to derive a total FSFI score. The domain scores range from 1.2 - 6, the overall score ranges from 7.2 - 36.
Overall operation timeintraoperativelyFrom the first cut to the end of the surgery
Cost of treatmentat discharge (approximately 10 days after surgery)Calculation using the length of hospitalization (days until discharge), suturing time, suture costs and needed transfusions)
Length of postoperative hospital stayat discharge (approximately 10 days after surgery)calculated by subtracting the surgery date from the date of discharge
Progress of Patient's abdominal pain (VAS 0-100) compared to baselinepreoperatively (baseline) and at discharge (up to 10 days after surgery), 6-8 weeks postoperatively, 6 months postoperativelyThe patient's self assessment of her abdominal pain. This parameter will be noted using the Visual Analogue Scale (VAS), represented by a line 10 cm of length, which states "0" at one end representing "no pain" and "100" at the opposite end representing "heavy pain". The value is measured in \[mm\] with a ruler and documented in whole numbers
Progress of Patient's pelvic pain (VAS 0-100) compared to baselinepreoperatively (baseline) and at discharge (up to 10 days after surgery), 6-8 weeks postoperatively, 6 months postoperativelyThe patient's self assessment of her pelvic pain. This parameter will be noted using the Visual Analogue Scale (VAS), represented by a line 10 cm of length, which states "0" at one end representing "no pain" and "100" at the opposite end representing "heavy pain". The value is measured in \[mm\] with a ruler and documented in whole numbers
Progress of Patient's lumbar pain (VAS 0-100) compared to baselinepreoperatively (baseline) and at discharge (up to 10 days after surgery), 6-8 weeks postoperatively, 6 months postoperativelyThe patient's self assessment of her lumbar pain. This parameter will be noted using the Visual Analogue Scale (VAS), represented by a line 10 cm of length, which states "0" at one end representing "no pain" and "100" at the opposite end representing "heavy pain". The value is measured in \[mm\] with a ruler and documented in whole numbers
Progress of General Health Status compared to baselinepreoperatively (baseline) and at discharge (up to 10 days after surgery), 6-8 weeks postoperatively, 6 months postoperativelyThe patient's self assessment of her general health status. Health status is based on assessment of the patient to the question, "Would you say your health in general is...:" The options are excellent / very good / good / fair / poor
Patient assessment of postoperative Dyspareuniaat both follow-up visits (6-8 weeks postoperatively and 6 months postoperatively)Dyspareunia is defined by genital pain that can be experienced before, during, or after intercourse. The patient answers with yes or no.
Assessment of the handling of the barbed suture (SYMMCORA®)intraoperativelyAssessment of the handling of the unidirectional barbed suture (SYMMCORA®) intra-operatively including eleven different dimensions (pliability, Pass-through, traumaticity, anchoring capacity, safety of closure, locking system size, locking system deployment, locking system unbarbed area, locking system safety of closure, atraumaticity, wound closure approximation) and an overall impression with 5 evaluations levels (excellent, very good, good, satisfied, poor).
Assessment of the handling of the barbed suture (SYMMCORA®) compared to conventional sutureintraoperativelyAssessment of the handling of the barbed suture (SYMMCORA®) compared to conventional suture regarding degree of difficulties and the ease of handling. (Likert Scale: strongly agree, agree, neither agree nor disagree, disagree, strongly disagree).
Assessment of the handling of the barbed suture (SYMMCORA®) compared to barbed suture (V-Loc)intraoperativelyAssessment of the barbed suture (SYMMCORA®) compared to barbed suture (V-Loc®) regarding smoothness, suppleness, traumaticity of the thread, the handling, the opening of the package and the overall opinion (Likert Scale: worse, equal, better).

Countries

Germany, Spain

Contacts

CONTACTPetra Baumann
petra.baumann@aesculap.de+49746195
PRINCIPAL_INVESTIGATORAmadeus Hornemann, Prof. Dr.

Klinikum Sachsenhausen der DGD

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 3, 2026